Introduction

Fibrosing mediastinitis (FM) is a rare, chronic inflammatory disease characterised by an increase in fibrous tissue within the mediastinum, the central area of the thoracic cavity. This condition can lead to significant health problems due to its potential to obstruct major mediastinal structures, including the airways, veins, and arteries. The aetiology of FM remains poorly understood, though it is often associated with granulomatous infections like histoplasmosis, as well as other autoimmune conditions. Given the complexity of FM and its variable presentation, effective monitoring and follow-up are crucial to managing patient outcomes and preventing complications.¹

Clinical presentation and diagnosis

The clinical presentation of FM can be insidious and variable, depending on the extent of mediastinal involvement and the structures affected. Symptoms can develop early and may include:³

• Chest pain
• Dyspnea
• Cough
• Weight loss
• Fever

However, when the superior vena cava (SVC) is affected, patients often report the following symptoms:

• Facial swelling
• Headaches
• Engorgement of the veins in the neck and/or chest wall

The diagnosis of FM is primarily based on imaging findings and tissue sample examination under a microscope. Computed tomography (CT) of the chest is the imaging modality of choice, revealing characteristic features such as dense mediastinal mass, lymphadenopathy, and the severity of involvement. 

An MRI scan is as good as a CT in diagnosing FM, however, it does not show calcification, hence not provide results of a suspected granulomatous FM. A biopsy and histological examination confirm the diagnosis by demonstrating fibrous tissue proliferation and ruling out other causes of a mediastinal mass.^1,4,5

Management strategies

Management of FM is challenging due to its heterogeneous nature. There is no standardised treatment regimen, and management often requires a multidisciplinary approach. The primary goals of treatment are to alleviate symptoms, prevent complications, and address the underlying cause if identified.

Medical management

• Corticosteroids: are frequently utilised to decrease inflammation and the formation of fibrous tissue. The effectiveness of these medications can differ, and reactions to treatment may be inconsistent. A common treatment plan could begin with a high dose of prednisolone, followed by a tapering schedule adjusted according to the patient's response and tolerance^1,2
• Immunosuppressive therapy: in situations where corticosteroids are insufficient or not recommended, options like methotrexate, azathioprine, or mycophenolate mofetil (MMF) might be taken into account^1,2,7

Surgical intervention

• Performing surgery is challenging because there is a significant risk of bleeding from enlarged collateral vessels. Surgical approaches have included tumour debulking, superior vena cava bypass using a spiral vein graft, and endovascular techniques like stenting or balloon angioplasty⁸

Management of complications

• Vascular complications: FM can cause encasement of major blood vessels, leading to thrombosis or compromised blood flow. Management may include anticoagulation therapy or surgical intervention if significant vascular compromise is present
• Airway complications: patients with FM may experience airway obstruction due to compression by fibrous tissue. Endoscopic procedures or stent placement might be required to maintain airway patency⁴

Monitoring strategies

Monitoring patients with FM is crucial for assessing disease progression, evaluating treatment efficacy, and managing complications. A comprehensive monitoring strategy includes regular clinical assessments, imaging studies, and laboratory tests.⁷

Clinical assessment

• Symptom tracking: regular assessment of symptoms such as dyspnea, chest pain, and cough helps gauge disease activity and response to treatment. Patient-reported outcomes and quality-of-life questionnaires can provide additional insights into the impact of FM on daily functioning
• Physical examination: routine physical examinations are essential for detecting signs of disease progression or complications, such as changes in breath sounds or signs of superior vena cava syndrome (SVCS)

Imaging studies

• CT scans: serial chest CT scans are used to monitor mediastinal mass changes and assess treatment response. These scans help identify any new complications, such as worsening obstruction or vascular involvement
• Magnetic resonance imaging (MRI): in certain cases, may provide additional information, particularly in assessing soft tissue involvement and distinguishing between fibrous tissue and other pathologies⁷

Laboratory tests

• Inflammatory markers: monitoring inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can provide indirect evidence of disease activity and response to treatment³
• Infectious disease testing: for patients with a known infectious aetiology, regular follow-up with microbiological testing is necessary to ensure that the infection is under control 

Long-term follow-up

Long-term follow-up is essential for patients with FM due to the chronic nature of the disease and the potential for late complications. Follow-up care typically involves:^5,4

Regular specialist visits

• Patients should have regular follow-ups with pulmonologists, cardiologists, or other specialists as needed, based on their specific symptoms and complications. These visits allow for ongoing assessment of disease status and adjustment of treatment plans

Patient education

• Educating patients about the nature of their condition, potential complications, and the importance of adherence to treatment and follow-up schedules is crucial for optimising outcomes. Patients should be informed about the warning signs of complications and when to seek medical attention

Psychosocial support

• Chronic diseases like FM can impact mental health and quality of life. Providing access to psychological support and counselling can help patients cope with the emotional and psychological aspects of living with a chronic illness

Summary

Fibrosing mediastinitis is a rare disease characterised by the growth of fibrous tissue in the mediastinum, leading to possible obstruction of critical structures like airways and blood vessels. Its causes are not well understood, but it may be related to infections and autoimmune diseases. Proper monitoring and follow-up are essential for effective management and to avoid complications.

FM can present with various symptoms depending on which structures are affected. Common symptoms include chest pain, difficulty breathing, cough, weight loss, and fever. Symptoms may worsen if the superior vena cava is impacted, causing facial swelling, headaches, and engorged neck veins.

Diagnosis relies on imaging tests, primarily CT scans, which show distinctive features like dense masses and lymph node enlargement. A biopsy can confirm the diagnosis by showing fibrous tissue. Managing FM is complex and often requires a team of specialists. There is no standard treatment; instead, the main objectives are to relieve symptoms, prevent complications, and tackle underlying causes whenever possible.

Corticosteroids are typically prescribed to reduce inflammation, although their effectiveness can vary. In cases where corticosteroids are insufficient, immunosuppressive drugs may be used to help control the disease. Surgery poses risks due to potential bleeding, but possible procedures can include tumour debulking or vascular bypass.

Complications may arise, particularly with blood vessels or the airway, requiring treatments like anticoagulation or endoscopic procedures. Patient monitoring is vital, involving regular assessments of symptoms, physical exams, imaging studies, and lab tests to track disease progression and response to treatment. Long-term follow-up care is fundamental for FM patients to manage chronic symptoms and complications effectively. This includes regular visits with specialists, patient education about the disease, and providing psychosocial support to help with the emotional impact of living with a chronic condition.